Access the full text.
Sign up today, get DeepDyve free for 14 days.
M Cornberg, HA Razavi, A Alberti, E Bernasconi, M Buti, C Cooper, O Dalgard, JF Dillion, R Flisiak, X Forns, S Frankova, A Goldis, I Goulis, W Halota, B Hunyady, M Lagging, A Largen, M Makara, S Manolakopoulos, P Marcellin, RT Marinho, S Pol, T Poynard, M Puoti, O Sagalova, S Sibbel, K Simon, C Wallace, K Young, C Yurdaydin, E Zuckerman, F Negro, S Zeuzem (2011)
A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelLiver Int, 31
(1999)
Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, BelgiumJ Viral Hepat, 6
CT Jones, CL Murray, DK Eastman, J Tassello, CM Rice (2007)
Hepatitis C virusp7 and NS2 proteins are essential for production of infectious virusJ Virol, 81
M Akram, M Idrees, S Zafar, A Hussain, S Butt, S Afzal, IU Rehman, A Liaqat, S Saleem, M Ali, A Butt (2011)
Effects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patientsVirol J, 8
E Alestig, B Arnholm, A Eilard, M Lagging, S Nilsson, G Norkrans, T Wahlberg, R Wejstål, J Westin, M Lindh (2011)
Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infectionBMC Infect Dis, 11
KA Stapleford, BD Lindenbach (2011)
Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1–E2 glycoprotein and NS3–NS4A enzyme complexesJ Virol, 85
H Kumada, J Toyota, T Okanoue, K Chayama, H Tsubouchi, N Hayashi (2012)
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in JapanJ Hepatol, 56
P Bedossa, T Poynard (1996)
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study GroupHepatology, 24
U Mihm, N Grigorian, C Welsch, E Herrmann, B Kronenberger, G Teuber, M Wagner, WP Hofmann, M Albrecht, T Lengauer, S Zeuzem, C Sarrazin (2006)
Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis CAntivir Ther, 11
B Ijaz, W Ahmad, FT Javed, S Gull, MT Sarwar, H Kausar, S Asad, S Jahan, S Khaliq, I Shahid, A Sumrin, S Hassan (2011)
Association of laboratory parameters with viral factors in patients with hepatitis CVirol J, 8
MP Manns, JG McHutchison, SC Gordon, VK Rustgi, M Shiffman, R Reindollar, ZD Goodman, K Koury, M Ling, JK Albrecht (2001)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialLancet, 358
H Okamoto, S Mishiro (1994)
Genetic heterogeneity of hepatitis C virusIntervirology, 37
M Idrees, S Riazuddin (2009)
A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patientsBMC Gastroenterol, 9
SD Griffin, LP Beales, DS Clarke, O Worsfold, SD Evans, J Jaeger, MP Harris, DJ Rowlands (2003)
The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, amantadineFEBS Lett, 535
JR Ticehurst, FM Hamzeh, DL Thomas (2007)
Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitisJ Clin Microbiol, 45
S Glisic, N Veljkovic, S Jovanovic Cupic, N Vasiljevic, J Prljic, B Gemovic, V Perovic, V Veljkovic (2012)
Asessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1bProtein J, 31
S Khaliq, S Jahan, S Hassan (2011)
Hepatitis C virus p7: molecular function and importance in hepatitis C virus life cycle and potential antiviral targetLiver Int, 31
Y Zeng, W Li, J Li, J Wang, B Zhou, J Zhang, S Liu, Y Wu, J Hou, Y Zhou (2012)
Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis CArch Virol, 157
FS Nolte, MW Fried, ML Shiffman, A Ferreira-Gonzalez, CT Garrett, ER Schiff, SJ Polyak, DR Gretch (2001)
Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus testsJ Clin Microbiol, 39
GA Cook, SJ Opella (2011)
Secondary structure, dynamics, and architecture of the p7 membrane protein from hepatitis C virus by NMR spectroscopyBiochim Biophys Acta, 1808
P Chomczynski, N Sacchi (1987)
Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extractionAnal Biochem, 162
RS Brown, PJ Gaglio (2003)
Scope of worldwide hepatitis C problemLiver Transpl, 9
RB Pollard (1999)
Analogy of human immunodeficiency virus to hepatitis C virus: the human immunodeficiency modelAm J Med, 107
AM Atoom, DM Jones, S Rodney, RS Russel (2013)
Evidence suggesting that HCV p7 protects E2 glycoprotein from premature degradation during virus productionVirus Res, 176
FT Javed, B Ijaz, W Ahmad, S Jahan, S Khaliq, S Hassan (2010)
Correlation of serum HCV titer, ALP and Bilirubin levels with liver fibrosis stageIJAVMS, 4
H Okamoto, Y Sugiyama, S Okada, K Kurai, Y Akahane, Y Sugai, T Tanaka, K Sato, F Tsuda, Y Miyakawa, M Mayumi (1992)
Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and infection sourcesJ Gen Virol, 73
S Chaves, MA Widdowson, A Bosman (2003)
Surveillance of HCV infection in the NetherlandsEuro Surveill, 8
G Antonucci, MA Longo, C Angeletti, F Vairo, A Oliva, UV Comandini, G Tocci, E Boumis, P Noto, MC Solmone, MR Capobianchi, E Girardi (2007)
The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yrAm J Gastroenterol, 102
JF Li, S Liu, F Ren, M Liu, HL Wu, Y Chen, HB Zou, L Bai, Y Li, SJ Zheng, ZP Duan (2014)
Fibrosis progression in interferon treatment-naive Chinese plasma donors with chronic hepatitis C for 20 years: a cohort studyInt J Infect Dis, 27
S Griffin (2010)
Inhibition of HCV p7 as a therapeutic targetCurr Opin Investig Drugs, 11
MS Forman, A Valsamakis (2004)
Verification of an assay for quantification of hepatitis C virus RNA by use of an analytic-specific reagent and two different extraction methodsJ Clin Microbiol, 42
V Saludes, MA Bracho, O Valero, M Ardèvol, R Planas, F González-Candelas, V Ausina, E Martró (2010)
Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factorsPLoS One, 5
KP Garnock-Jones (2012)
Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infectionDrugs, 72c
AL Wozniak, S Griffin, D Rowlands, M Harris, M Yi, SM Lemon, SA Weinman (2010)
Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus productionPLoS Pathog, 6
KH Kim, BK Jang, WJ Chung, JS Hwang, YO Kweon, WY Tak, HJ Lee, CH Lee, JI Suh (2011)
Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosisKorean J Hepatol, 7
J Velosa, F Serejo, T Bana, I Redondo, A Simão, AM Vale, S Pires, G Macedo, R Marinho, P Peixe, J Sarmento, L Matos, F Calinas, A Carvalho, A Figueiredo (2011)
Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practiceHepatogastroenterology, 58
MW Fried, ML Shiffman, KR Reddy, C Smith, G Marinos, FL Goncales, Haussinger JrD, M Diago, G Carosi, D Dhumeaux, A Craxi, A Lin, J Hoffman, J Yu (2002)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med, 347
S Carrère-Kremer, C Montpellier-Pala, L Cocquerel, C Wychowski, F Penin, J Dubuisson (2002)
Subcellular localization and topology of the p7 polypeptide of hepatitis C virusJ Virol, 76
JG McHutchison, GT Everson, SC Gordon, IM Jacobson, M Sulkowski, R Kauffman, L McNair, J Alam, AJ Muir (2009)
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infectionN Engl J Med, 360
RJ Galán, EC Cidoncha, MF Martin, CC Rodriguez, CV Almeida, RM Verdugo (2013)
Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis CJ Manag Care Pharm, 19
LB Costa, ML Ferraz, RM Perez, AS Ferreira, CA Matos, VP Lanzoni, AE Silva (2002)
Effect of host-related factors on the intensity of liver fibrosis in patients with chronic hepatitis C virus infectionBraz J Infect Dis, 6
S Liu, W Yang, L Shen, JR Turner, CB Coyne, T Wang (2009)
Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfectionJ Virol, 83
N Svirtlih, D Delic, J Simonovic, D Jevtovic, L Dokic, E Gvozdenovic, I Boricic, D Terzic, S Pavic, G Neskovic, S Zerjav, V Urban (2007)
Hepatitis C virus genotypes in Serbia and Montenegro: the prevalence and clinical significanceWorld J Gastroenterol, 13
P Muñoz de Rueda, J Casado, R Patón, D Quintero, A Palacios, A Gila, R Quiles, J León, A Ruiz-Extremera, J Salmerón (2008)
Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responsesJ Virol, 82
T Poynard, P Bedossa, P Opolon (1997)
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groupsLancet, 349
M Fusco, E Girardi, P Piselli, R Palombino, J Polesel, C Maione, P Scognamiglio, FA Pisanti, M Solmone, P Cicco, G Ippolito, S Franceschi, D Serraino (2008)
Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancerEur J Cancer, 44
SH Chen, SL Tan (2005)
Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infectionCurr Med Chem, 12
H Li, E Atkins, J Bruckner, S McArdle, WC Qiu, LV Thomassen, J Scott, MC Shuhart, S Livingston, L Townshend-Bulson, BJ McMahon, M Harris, S Griffin, DR Gretch (2012)
Genetic and functional heterogeneity of the hepatitis C virus p7 ion channel during natural chronic infectionVirology, 423
V Saludes, E Bascunana, E Jordana-Lluch, S Casanovas, M Ardevol, E Soler, R Planas, V Ausina, E Martró (2013)
Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected PatientsPLoS One, 8
A Kau, J Vermehren, C Sarrazin (2008)
Treatment predictors of a sustained virologic response in hepatitis B and CJ Hepatol, 49
AJ Michaels, DR Nelson (2010)
New therapies in the management of hepatitis C virusCurr Opin Gastroenterol, 26
T Asselah, I Bieche, V Paradis, P Bedossa, M Vidaud, P Marcellin (2007)
Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis CSemin Liver Dis, 27
The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy ( p < 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis ( p < 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) ( p < 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.
Archives of Virology – Springer Journals
Published: May 1, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.